(135 days)
No
The description focuses on a standard immunochemical reaction and light scattering measurement, with no mention of AI or ML terms or processes.
No
This device is for in vitro diagnostic (IVD) use, specifically for measuring ceruloplasmin and hemopexin in human serum and plasma. It aids in diagnosis but does not directly treat or prevent a disease, which is the function of a therapeutic device.
Yes
The "Intended Use / Indications for Use" section explicitly states "In vitro diagnostic reagents for the quantitative determination of ceruloplasmin and hemopexin in human serum..." and "Measurement of ceruloplasmin aids in the diagnosis of cooply of metabolism disorders," clearly indicating its use for diagnosis.
No
The device description clearly states it is an in vitro diagnostic reagent, which is a physical substance used in laboratory tests, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The text explicitly states "In vitro diagnostic reagents for the quantitative determination of ceruloplasmin and hemopexin in human serum and heparinization of only and one of immunonephelometry on the BN™ Systems." and "In vitro diagnostic reagents for the quantitative determination of ceruloplasmin and hemopexin in serum and heparinized plasma by means of immunonephelometery on the BN™ Systems." This clearly indicates the device is intended for use outside of the body to diagnose or aid in the diagnosis of conditions (specifically, "cooply of metabolism disorders" by measuring ceruloplasmin).
- Device Description: The description details a method for analyzing components of human body fluids (proteins in serum and plasma) using an immunochemical reaction and light scattering, which is a common technique in in vitro diagnostics.
- Predicate Device: The mention of a predicate device (K860894; N Antisera to Human Ceruloplasmin) further supports its classification as an IVD, as predicate devices are used to demonstrate substantial equivalence for regulatory purposes for IVDs.
The core function of the device is to analyze biological samples (serum and plasma) outside of the body to provide information for diagnostic purposes, which is the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
In vitro diagnostic reagents for the quantitative determination of ceruloplasmin and hemopexin in human serum and heparinization of only and one of immunonephelometry on the BN™ Systems.
Indications for Use:
In vitro diagnostic reagents for the quantitative determination of ceruloplasmin and hemopexin in serum and heparinized plasma by means of immunonephelometery on the BN™ Systems. Measurement of ceruloplasmin aids in the diagnosis of cooply of metabolism disorders.
Product codes
DDB
Device Description
Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the relevant protein in the sample. The result is evaluated by comparison with a standard of known concentration.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
To demonstrate equivalence in measurement between serum and heparinized plasma, a method comparison was performed. This study demonstrates equivalent performance with a correlation coefficient of 0.99
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.5210 Ceruloplasmin immunological test system.
(a)
Identification. A ceruloplasmin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the ceruloplasmin (copper-transporting serum protein) in serum, other body fluids, or tissues. Measurements of ceruloplasmin aid in the diagnosis of copper metabolism disorders.(b)
Classification. Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
0
510(k) Summary for N Antisera to Human Ceruloplasmin
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: ___
1. Manufacturer's Name, Address, Telephone, and Contact Person, Date of Preparation:
Manufacturer:
Dade Behring Marburg GmbH Emil-von-Behring Str. 76 D-35001 Marburg, Germany
Contact Information:
Dade Behring Inc. Glasgow Site P.O. Box 6101 Newark, Delaware 19714 Attn: Kathleen Dray-Lyons Tel: 781-826-4551 Fax: 781-826-2497
Preparation date:
February 17, 2006
-
- Device Name/ Classification: N Antisera to Human Ceruloplasmin Class: Ceruloplasmin Immunological Test System, Class II, 21 CFR 866.5210 Panel: Immunology Product Code: DDB
3. Identification of the Legally Marketed Device:
N Antisera to Human Ceruloplasmin- K860894
4. Device Description:
Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the relevant protein in the sample. The result is evaluated by comparison with a standard of known concentration.
1
5. Device Intended Use:
In vitro diagnostic reagents for the quantitative determination of ceruloplasmin and hemopexin in human serum and heparinization of only and one of immunonephelometry on the BN™ Systems.
ର, Medical device to which equivalence is claimed and comparison information:
The modified N Antisera to Human Ceruloplasmin assay is substantially equivalent to the N Antisera to Human Ceruloplasmin currently marketed (K860894). The modified N Antisera to Human Ceruloplasmin assay, like the current N Antisera to Human Ceruloplasmin assay, is intended for the carrent in Yrintsera to Hulfall means of immunonephelometry on the BN™ Systems.
7. Device Performance Characteristics:
To demonstrate equivalence in measurement between serum and heparinized plasma, a method comparison was performed. This study demonstrates equivalent performance with a correlation coefficient of 0.99
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three lines forming its body and wings. The eagle is enclosed in a circle of text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".
Public Health Service
Food and Druq Administration 2098 Gaither Road Rockville MD 20850
MAR 16 2006
Dade Behring, Inc. c/o Ms. Kathleen A Dray-Lyons Glasgow Site P.O. Box 6101 Newark, DE 19714
Re: K053074
Trade/Device Name: N Antisera to Human Ceruloplasmin Regulation Number: 21 CFR 866.5210 Regulation Name: Ceruloplasmin immunological test system Regulatory Class: Class II Product Code: DDB Dated: October 28, 2005 Received: November 1, 2005
Dear Ms. Dray-Lyons:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally promated predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Robert H. Becker/
Robert L. Becker, Jr., M.D., Ph.p. Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indications Statement
Device Name: N Antisera to Human Ceruloplasmin Assay
Indications for Use:
In vitro diagnostic reagents for the quantitative determination of ceruloplasmin and hemopexin in serum and heparinized plasma by means of immunonephelometery on the BN™ Systems. Measurement of ceruloplasmin aids in the diagnosis of cooply of metabolism disorders.
X Prescription Use (Per 21 CFR 801 Subpart D)
Over-The-Counter-Use_ (21 CFR 801)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Page 1 of
Mana Chan
The of In Vitro Diagnostic Device Safen and Safety
000008